Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...

Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that ...

EVO301, a long-acting, injectable interleukin-18 binding protein, rapidly improved moderate to severe atopic dermatitis in ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

Phase 3 PEACE trial data support the accelerated approval of Loargys for the treatment of arginase 1 deficiency in pediatric and adult patients.

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Monday that the European Commission has approved subcutaneous Rybrevant (amivantamab) for every-three-week and every-four-week dosing schedules ...

Karnataka launches 'Kusuma Sanjeevini' program, providing free prophylactic treatment and transport for hemophilia patients, enhancing their quality of life.

New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

Anifrolumab, a type I interferon receptor antagonist, is already approved as an intravenous (IV) therapy for SLE. The TULIP-SC trial was designed to evaluate whether a weekly subcutaneous (SC) ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...